Cargando…

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

BACKGROUND: Prostate-specific antigen (PSA) is widely used to detect prostate cancer. The low positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies. We set out to determine whether a multivariable model including four kallikrein forms (total, free, and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vickers, Andrew J, Cronin, Angel M, Aus, Gunnar, Pihl, Carl-Gustav, Becker, Charlotte, Pettersson, Kim, Scardino, Peter T, Hugosson, Jonas, Lilja, Hans
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2474851/ https://www.ncbi.nlm.nih.gov/pubmed/18611265 http://dx.doi.org/10.1186/1741-7015-6-19

Ejemplares similares

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial
por: Frånlund, Maria, et al.
Publicado: (2022)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
por: Wallström, Jonas, et al.
Publicado: (2021)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
por: Benchikh, Amine, et al.
Publicado: (2010)

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate
por: Kohestani, Kimia, et al.
Publicado: (2021)

Pediatric chronic non-bacterial osteomyelitis in Goteborg, Sweden
por: Berg, S, et al.
Publicado: (2015)

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
por: Bryant, Richard J., et al.
Publicado: (2015)

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

Kallikreins as Biomarkers for Prostate Cancer
por: Hong, Sung Kyu
Publicado: (2014)

VIP visit to CMS by Prof. Lars Brink / Chalmers University Goteborg Sweden
por: Hoch, Michael
Publicado: (2014)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2010)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study
por: Stattin, Pär, et al.
Publicado: (2010)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
por: Ulmert, David, et al.
Publicado: (2008)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Kallikrein gene family as biomarkers for recurrent prostate cancer
por: Busra Boyukozer, Fatma, et al.
Publicado: (2020)

Expression of kallikrein-related peptidase 7 is decreased in prostate cancer
por: Zhang, Chong-Yu, et al.
Publicado: (2015)

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
por: Timmermand, Oskar Vilhelmsson, et al.
Publicado: (2014)

Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies
por: Steuber, Thomas, et al.
Publicado: (2018)

Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy
por: Satkunasivam, Raj, et al.
Publicado: (2014)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
por: Vilhelmsson Timmermand, O., et al.
Publicado: (2016)

Ultrasound‐based radiomics score for pre‐biopsy prediction of prostate cancer to reduce unnecessary biopsies
por: Ou, Wei, et al.
Publicado: (2022)

Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies
por: Wang, Changming, et al.
Publicado: (2022)

Structural brain changes in hyperthyroid Graves’ disease: protocol for an ongoing longitudinal, case-controlled study in Göteborg, Sweden—the CogThy project
por: Holmberg, Mats Olof, et al.
Publicado: (2019)

Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application
por: Fuhrman-Luck, Ruth A., et al.
Publicado: (2014)

Association between three genetic variants in kallikrein 3 and prostate cancer risk
por: Ding, Wei-Hong, et al.
Publicado: (2018)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2013)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
por: Bertok, Tomas, et al.
Publicado: (2020)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies
por: Zhang, Li, et al.
Publicado: (2022)

A Prospective Study of Reducing Unnecessary Prostate Biopsy in Patients with High Serum Prostate-Specific Antigen with Consideration of Prostatic Inflammation
por: Lee, An Gu, et al.
Publicado: (2012)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
por: Klein, Robert J., et al.
Publicado: (2022)

An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
por: Jager, Auke, et al.
Publicado: (2022)

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project
por: Assel, Melissa J., et al.
Publicado: (2017)

The percentage of high‐grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death
por: Berney, Daniel M, et al.
Publicado: (2019)

The Value of Low Prostate Imaging—Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies
por: Kim, Dong-Soo, et al.
Publicado: (2021)

A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy
por: Haese, Alexander, et al.
Publicado: (2020)

Circulating microRNAs and Kallikreins before and after Radical Prostatectomy: Are They Really Prostate Cancer Markers?
por: Egidi, Maria Giulia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_m9adlkfjhvb0f5gr1vv9ir4ori